Episode 56
Biotech Hangout
00:00
The Tough Times Raising Money, but Some Strength on the Public Markets
Snofe already has a commercial relationship with prevention. It is bizarre that a company that has no interest in, you know, type one diabetes would be getting reviewed by the FTC. In terms of headwinds, it's unfortunate that there's now a political headwind with the pepperstone story earlier this week. The big concern for our industry is that this would be a precedent for the judicial system who are not experts to overturn drug approvals without regard for signs or evidence based on political grounds.
Transcript
Play full episode
